β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now?
Open Access
- 1 June 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Vascular Health and Risk Management
- Vol. ume 17, 337-348
- https://doi.org/10.2147/vhrm.s285907
Abstract
β-blockers are a heterogeneous class of drugs, with varying selectivity/specificity for β1 vs β2 receptors, intrinsic sympathomimetic activity (ISA), and vasodilatory properties (through β2 stimulation, α receptor blockade or nitric oxide release). These drugs are indicated for the management of arterial hypertension, heart failure or ischemic heart disease (IHD; eg angina pectoris or prior myocardial infarction). Most of the benefit of β-blockade in these conditions arises from blockade of the β1 receptor, and, in practice, the addition of ISA appears to reduce the potential for improved clinical outcomes in people with heart failure or IHD. Aspects of the benefit/risk balance of β-blockers remain controversial, and recent meta-analyses have shed new light on this issue. We have reviewed the current place of cardioselective β-blockade in hypertension, IHD and heart failure, with special reference to the therapeutic profile of a highly selective β1-adrenoceptor blocker, bisoprolol.Keywords
This publication has 87 references indexed in Scilit:
- Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: Recommendations for patient informationInternational Journal of Cardiology, 2013
- Benefits of blockers in patients with heart failure and reduced ejection fraction: network meta-analysisBMJ, 2013
- Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic controlCardiovascular Diabetology, 2012
- Inverse agonism and its therapeutic significanceIndian Journal of Pharmacology, 2011
- Effects of β-blockers on glucose and lipid metabolismCurrent Medical Research and Opinion, 2010
- Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ, 2009
- Are we misunderstanding beta-blockersInternational Journal of Cardiology, 2007
- Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trialEuropean Heart Journal, 2005
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureThe New England Journal of Medicine, 1996
- Effect of beta blockers on blood lipid profileAmerican Heart Journal, 1985